Wolfe Research Lowers Cigna (CI) Price Target but Keeps Outperform Rating

Core Viewpoint - The Cigna Group (NYSE:CI) is considered a cheap stock by analysts, with Wolfe Research lowering its price target from $345 to $325 while maintaining an Outperform rating, indicating potential for investment growth [1][2]. Group 1: Price Target and Valuation - Wolfe Research has revised its price target for The Cigna Group from $345 to $325, reflecting a slight moderation in its forecasts [1]. - The stock is currently valued at approximately 9 times its revised 2026 EPS forecast, suggesting it is undervalued [1]. Group 2: Business Performance and Outlook - The Cigna Group is expected to benefit from margin recovery efforts in its Stop Loss business, indicating a positive outlook for this segment [2]. - The Evernorth division is anticipated to continue delivering solid performance, contributing to the overall strength of The Cigna Group [2]. - The company is viewed as defensively positioned amid current uncertainties in government regulations within the healthcare industry [2]. Group 3: Company Overview - The Cigna Group is a multinational managed healthcare and insurance company, offering products and services under Cigna Healthcare, Evernorth Health Services, and other subsidiaries [3].